News from NORD

NORD Seeks Input Regarding Patient Protections and ACA


 

As the new administration and Congress consider replacing the Affordable Care Act with a new system, NORD is seeking input from patients and health care providers for its advocacy on behalf of rare disease patients. Patients or providers who have experiences or concerns to share regarding pre-existing conditions, annual or lifetime insurance caps, high-risk pools, or other topics may share their experiences with NORD.

Recommended Reading

Brentuximab vedotin beat methotrexate, bexarotene in cutaneous T-cell lymphoma
MDedge Hematology and Oncology
January 13 Is Deadline for NORD Rare Impact Award Nominations
MDedge Hematology and Oncology
Major Three-Year Study of Undiagnosed Diseases Announced
MDedge Hematology and Oncology
PERSIST-2 might allay some concerns about pacritinib in myelofibrosis
MDedge Hematology and Oncology
VIDEO: Despite toxicities, ibrutinib is beneficial for treatment-resistant graft-vs.-host disease
MDedge Hematology and Oncology
Nominate a Patient or Colleague for a NORD Rare Impact Award
MDedge Hematology and Oncology
Join Others Around the World in Observing Rare Disease Day
MDedge Hematology and Oncology
AWaRDS Study Examines Services for Adults With Rare Disorders
MDedge Hematology and Oncology
NORD Report Shows Majority of States Fall Short on Reducing Burden of Living With a Rare Disease
MDedge Hematology and Oncology
Nivolumab safe, effective for salvage in advanced gastric cancer
MDedge Hematology and Oncology